緑内障治療に向けた独自形状のマイクロステントを開発(Oxford researchers develop uniquely shaped microstent to combat glaucoma)

ad

2025-08-21 オックスフォード大学

オックスフォード大学の研究チームは、緑内障治療のために新しい展開式マイクロステントを開発しました。直径200µm程度の極小サイズで、注射針を通して眼内に挿入でき、配置後に展開して白目と膜の間の流体スペースを支える仕組みです。これにより眼圧を下げ、視神経損傷を防ぐ効果が期待されます。ウサギでの試験では1か月以内に眼圧が低下し、炎症や瘢痕もほとんど観察されませんでした。従来の管状インプラントよりも効果が高いことも示されています。ステントはニチノール合金製で超弾性を持ち、眼の形状変化に追従できるよう設計され、移動やずれを防ぎます。本成果は、低侵襲で長期安定性の高い治療法として、緑内障手術の将来に新たな選択肢を提示するものです。

緑内障治療に向けた独自形状のマイクロステントを開発(Oxford researchers develop uniquely shaped microstent to combat glaucoma)
Scanning electronic microscopy image of the microstent. Credit: Yunlan, Zhang, Zhong You, Jared Ching.

<関連情報>

緑内障の治療のための新たな展開可能なマイクロステント A novel deployable microstent for the treatment of glaucoma

Yunlan Zhang ∙ Weijia Zhang ∙ Yunfang Yang ∙ … ∙ Chun Zhang ∙ Zhong You ∙ Jared Ching
The Innovation  Published:April 29, 2025
DOI:https://doi.org/10.1016/j.xinn.2025.100935

Dear Editor,

Glaucoma is the second leading cause of blindness worldwide, after cataracts, and results in irreversible optic nerve damage and vision loss.1 The most common subtype, primary open-angle glaucoma (POAG), is caused by impaired aqueous humor (AH) drainage through the trabecular meshwork. POAG progresses gradually, often without symptoms until significant vision loss occurs. Treatments focus on lowering IOP using medicated eye drops, laser therapy, or surgical interventions. In the past decade, minimally invasive glaucoma surgery (MIGS) has emerged as a safer alternative to traditional surgeries, aiming to reduce IOP with minimal scleral or conjunctival disruption and a lower risk of fibrosis. MIGS devices improve AH drainage through the SCS, Schlemm’s canal, or the suprachoroidal space (Figure 1A). Among these approaches, tubular implants that drain from the anterior chamber (AC) to the SCS have demonstrated the most significant IOP reduction.2,3 Constructed from soft, biocompatible materials such as porcine gelatin and poly(styrene-block-isobutylene-block-styrene), these devices emulate traditional trabeculectomy surgery by forming a subconjunctival bleb, which is known for its potent IOP-lowering capabilities.4 However, clinical studies5 have revealed that the long-term effectiveness of these implants falls short of trabeculectomy due to issues like fibrosis and the eventual loss of bleb function, even with the use of anti-fibrosis medications.6 Additionally, these devices are susceptible to breakage and migration over time.

Figure 1 Design, fabrication, and experimental testing of the deployable microstent

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました